DBV Technologies Shares Consolidate Late Afternoon Following a 14% Drop Over Seven Days
DBV Technologies shares saw a slight increase of 0.14% this Tuesday, March 17, 2026, trading at €3.465, after experiencing significant selling pressure over the past week. Over the last seven days, the stock has declined by 14.23%, triggering a signal of abnormal fluctuation. This movement contrasts with the performance of the CAC 40, which is up by 0.88% during the session.
DBV Technologies has undergone a noticeable weekly correction, bringing its price close to the technical support level at €3.43. The monthly volatility of the stock stands at 17.31%, reflecting significant price ranges during the recent period. This movement occurs in a moderately tense global environment, with the VIX remaining at 27.19, a level indicating persistent nervousness in international markets. The stock is trading significantly below its 50-day moving average of €3.64, confirming an unfavorable short-term dynamic. The RSI is at 38, signaling a gradual approach to the oversold zone without yet crossing it.
Long-Term Outlook and Technical Indicators
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Over a longer horizon, DBV Technologies has shown a spectacular recovery of 293.8% over the past twelve months. The performance over three months remains slightly positive at 1.02%, placing the recent correction in a consolidation phase after a significant bullish phase. The stock is also trading well above its 200-day moving average, set at €2.49, maintaining a bullish backdrop over the long term. The technical resistance identified at €4.27 remains distant from the current prices, while a beta of 0.43 illustrates a moderate correlation of the stock with overall market movements. The MACD signal, slightly negative, further confirms the persistence of short-term pressure on the stock.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.